Lactobacillus acidophilus
EVIDENCE: MIXEDAlso sold as: L. acidophilus, LA88, L. acidophilus GLA-14, acidophilus
Some L. acidophilus strains have been studied as oral additions to antibiotic treatment for bacterial vaginosis. Evidence for urinary effects is indirect, and bladder-control benefits are not established. A species name alone does not identify the researched strain.
Compiled by iSupplementReviews editorial team ·Updated 2026-10-10 · 4 sources
- Type
- Probiotic — vaginal/GI species
- Studied dose
- 1–10 billion CFU/day orally (BV trials), typically in multi-strain formulas
- Best form
- Named strain + CFU count; evidence lives in multi-strain combinations, not solo acidophilus
- Our rating
- MIXED — Some human evidence, inconsistent or indirect
What is Lactobacillus acidophilus?
L. acidophilus is a probiotic species found in the gut, mouth, and vagina, with a long history in fermented-food products. It is part of vaginal bacterial communities, but is not the dominant protective species associated with the strongest L. crispatus research.
Other names and forms it’s sold as
- DDS-1, NCFM, GLA-14, LA88: commercial strain designations; each is a distinct organism
- Single-strain capsules or multi-strain blends (the form with actual trial evidence)
- Fermented dairy: the traditional vehicle
Where does it come from?
Fermented dairy and the human digestive tract. Supplement strains are cultured industrial isolates. “Acidophilus” on a label says almost nothing about which organism you’re getting unless a strain ID follows it.
How does it work in the body?
Like other vaginal lactobacilli: lactic-acid production lowers vaginal pH to the <4.5 range that suppresses Gardnerella and other problem bacteria, plus competitive exclusion of pathogens. In the gut it modestly supports digestion and tolerates stomach acid better than most species, hence its dominance in oral products.
What is it claimed to do?
Digestive health (its legitimate home), vaginal flora support, immune support, and, by extension in urinary formulas, protection against urinary pathogens.
What does the research show?
| Claim | Evidence | Dose studied | Verdict |
|---|---|---|---|
| BV recurrence prevention (adjunct to antibiotics) | Multiple trials, always in combinations | ~5–10B CFU/day oral | Supported — in combos |
| Vaginal colonization after oral dose | Some strains documented | 10⁹+ CFU/day | Plausible, strain-dependent |
| UTI prevention | No direct human trials | — | Unproven |
| Bladder leaks / urgency | None | — | No evidence |
The BV adjunct trials — where the real evidence sits
Trials of specific multi-ingredient lactobacillus preparations found reduced or delayed bacterial-vaginosis recurrence. Those results do not isolate L. acidophilus or apply to every strain or product.
The prOVag trial (BMC Women’s Health, 2015): 578 women on an oral three-strain lactobacillus (including acidophilus) alongside metronidazole saw BV/aerobic-vaginitis relapse delayed ~51% vs placebo, with vaginal pH and lab scores held lower. Russo et al. (2019): L. acidophilus GLA-14 + L. rhamnosus HN001 + lactoferrin significantly cut 6-month BV recurrence. The 2010 AJOG vaginal-capsule trial (acidophilus + rhamnosus + thermophilus, 8 billion CFU) showed similar protection, vaginally.
The consistent pattern: acidophilus works as a team player after antibiotic disruption, for vaginal outcomes. Extending that to “protects your bladder from leaks” is marketing, not evidence.
What dose was studied?
| Goal | Dose | Form/route | Duration |
|---|---|---|---|
| BV recurrence (adjunct) | 5–10B CFU/day | oral, multi-strain | weeks–months |
| Vaginal BV prophylaxis | ~8B CFU | vaginal capsule | intermittent cycles |
Side effects
Essentially none in healthy people; gas or mild bloating in the first week is the worst of it. Rare class-level bloodstream-infection reports apply only to severely immunocompromised patients.
Drug interactions
- Antibiotics: space doses or take after the course ends
- Immunosuppressants: the standard probiotic caution for the severely immunocompromised
Who should not take it?
Severely immunocompromised patients. For everyone else it’s among the safest substances sold.
What the authorities say
NCCIH classifies lactobacilli as safe with plausible digestive support. The 2024 Lancet Microbe review maps L. acidophilus as a real but secondary member of the protective cervicovaginal flora: present in healthy women, but not the keystone species L. crispatus is. ISAPP’s strain-specificity consensus applies: benefits demonstrated in GLA-14 or LMG S-29995 formulas don’t automatically attach to a different strain on a different label.
What to know about Lactobacillus acidophilus
Some L. acidophilus preparations have evidence as additions to vaginal-health treatment. Direct bladder benefits are not established. Strain identity, live-bacteria count, and the studied combination are needed before applying those findings to a capsule.
Frequently asked questions about Lactobacillus acidophilus
Does Lactobacillus acidophilus help urinary health?
Indirectly at best. Its human trial record is for vaginal outcomes: as part of multi-strain formulas that reduce BV recurrence after antibiotics (e.g., the prOVag trial delayed relapse ~51%). No trial shows oral L. acidophilus reaching the bladder or reducing UTI or leakage.
Is acidophilus effective on its own?
Almost never studied solo for urogenital outcomes. The positive trials combined it with L. crispatus, L. brevis, L. rhamnosus, or lactoferrin. Multi-strain products can reasonably claim that evidence; single-strain acidophilus claims are extrapolation.
What's the effective dose of L. acidophilus?
BV trials used multi-billion-CFU daily doses (e.g., 5.4 billion CFU/day in combination). Milligram amounts on a label are meaningless for probiotics; the unit that predicts effect is CFU (colony-forming units, the count of live bacteria), and a product that lists only mg hasn't disclosed its dose.
Is L. acidophilus safe?
Very. It's the longest-marketed probiotic species with a decades-long safety record in foods and supplements. Standard caution: severely immunocompromised patients have rare bloodstream-infection case reports across the probiotic class.
References
- [1]Oral probiotics + metronidazole for BV/AV recurrence — prOVag multicentre RCT (BMC Women's Health, 2015)
- [2]L. acidophilus GLA-14 + L. rhamnosus HN001 + lactoferrin for recurrent BV — RCT (Beneficial Microbes, 2019)
- [3]L. acidophilus in the cervicovaginal microenvironment — review (Lancet Microbe, 2024)
- [4]Vaginal probiotic capsules (acidophilus/rhamnosus/thermophilus) for recurrent BV — RCT (AJOG, 2010)
Products we reviewed containing Lactobacillus acidophilus
Based on recorded labels or seller-described formulas. Inclusion does not establish a match to the strains, preparations or amounts studied here; check each review's disclosure limits.